586 related articles for article (PubMed ID: 25596660)
1. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
2. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
4. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY; Ferris RL; Psyrri A; Haddad RI; Tahara M; Bourhis J; Harrington K; Chang PM; Lin JC; Razaq MA; Teixeira MM; Lövey J; Chamois J; Rueda A; Hu C; Dunn LA; Dvorkin MV; De Beukelaer S; Pavlov D; Thurm H; Cohen E
Lancet Oncol; 2021 Apr; 22(4):450-462. PubMed ID: 33794205
[TBL] [Abstract][Full Text] [Related]
5. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
[TBL] [Abstract][Full Text] [Related]
7. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA;
Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
9. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
10. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J; Sire C; Graff P; Grégoire V; Maingon P; Calais G; Gery B; Martin L; Alfonsi M; Desprez P; Pignon T; Bardet E; Rives M; Geoffrois L; Daly-Schveitzer N; Sen S; Tuchais C; Dupuis O; Guerif S; Lapeyre M; Favrel V; Hamoir M; Lusinchi A; Temam S; Pinna A; Tao YG; Blanchard P; Aupérin A
Lancet Oncol; 2012 Feb; 13(2):145-53. PubMed ID: 22261362
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
12. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
13. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.
Haddad R; O'Neill A; Rabinowits G; Tishler R; Khuri F; Adkins D; Clark J; Sarlis N; Lorch J; Beitler JJ; Limaye S; Riley S; Posner M
Lancet Oncol; 2013 Mar; 14(3):257-64. PubMed ID: 23414589
[TBL] [Abstract][Full Text] [Related]
16. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
17. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
[TBL] [Abstract][Full Text] [Related]
18. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
19. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
